Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 95

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 95
---
| Operating expenses                                                                                                      | ​ | ​ | ​                                                   | ​ |      7,130 | ​ | ​ | ​ | ​                                             | ​ |      7,130 | ​ | ​ |
| Loss from operations                                                                                                    | ​ | ​ | ​                                                   | ​ |     -7,130 | ​ | ​ | ​ | ​                                             | ​ |     -7,130 | ​ | ​ |
| Net loss                                                                                                                | ​ | ​ | ​                                                   | ​ |    -10,500 | ​ | ​ | ​ | ​                                             | ​ |    -10,500 | ​ | ​ |
| Basic and diluted net loss per share                                                                                    | ​ | ​ | ​                                                   | $ |      -0.39 | ​ | ​ | ​ | ​                                             | $ |      -0.39 | ​ | ​ |
| Basic and diluted weighted average shares outstanding                                                                   | ​ | ​ | ​                                                   | ​ | 26,774,477 | ​ | ​ | ​ | ​                                             | ​ | 26,600,000 | ​ | ​ |
| Summary Unaudited Pro Forma Condensed Combined Balance SheetData as of September 30, 2024                               | ​ | ​ | ​                                                   | ​ |          ​ | ​ | ​ | ​ | ​                                             | ​ |          ​ | ​ | ​ |
| Total assets                                                                                                            | ​ | ​ | ​                                                   | $ |      5,093 | ​ | ​ | ​ | ​                                             | $ |      3,158 | ​ | ​ |
| Total liabilities                                                                                                       | ​ | ​ | ​                                                   | $ |     14,173 | ​ | ​ | ​ | ​                                             | $ |     14,192 | ​ | ​ |
| Total equity                                                                                                            | ​ | ​ | ​                                                   | $ |     -9,080 | ​ | ​ | ​ | ​                                             | $ |    -11,034 | ​ | ​ |

25

TABLE OF CONTENTS

### RISK FACTORS
You should carefully consider the following risk factors, in addition to the other information included in this proxy statement/prospectus, including matters addressed in the section entitled “Cautionary Note Regarding Forward-Looking Statements” and the financial statements and notes to the financial statements included herein. In addition, you should read and consider the risks associated with the business of Iris because these risks may also affect ParentCo — these risks can be found in Iris’s Annual Report on Form 10-K,